Second-line medical treatment for nonsmall cell lung cancer: what the studies say

Y. Sekine (Chiba, Japan)

Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not?

Session: Lung cancer progress after first-line therapy: which treatment makes sense and which does not?
Session type: Symposium
Number: 3618

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Sekine (Chiba, Japan). Second-line medical treatment for nonsmall cell lung cancer: what the studies say. Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not?

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Second-line medical treatment for nonsmall cell lung cancer: what happens in reality Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not? Year: 2010
PRO: maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer Source: Annual Congress 2011 - Pro/Con debate: Maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer Year: 2011
First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014
Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009
Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011
Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012
Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Use of 2^nd-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Combined radiotherapy for nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Delays in the diagnosis and treatment of non-small cell lung cancer Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010
Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012